Tirz

Tirzepatide (the compound behind Mounjaro and Zepbound) is a dual-agonist peptide that works on two appetite and blood-sugar pathways — GLP-1 and GIP. Most peptides in this class only hit GLP-1, which is why Tirz is studied for stronger appetite control and glycemic results than single-agonist peptides. GLP-1 curbs appetite, slows how fast the stomach empties, and improves insulin response. GIP adds to insulin signaling and is studied for how the body stores and uses fat. In research protocols it is typically dosed twice weekly — that's a research cadence, not a purchase cadence — and is studied for weight, blood sugar, and metabolic health endpoints. Sold as a research reference standard for in-vitro laboratory use only. Not a drug, dietary supplement, food, cosmetic, or medical device. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any condition.

For research use only. Not for human or veterinary use. This product must be handled by trained personnel in accordance with institutional biosafety guidelines.